CBR1 Recombinant Antibody, FITC Conjugated
Product Specifications
Background
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol.
Synonyms
15 hydroxyprostaglandin dehydrogenase [NADP+]; Carbonyl reductase [NADPH] 1; CBR1; CRN; NADPH dependent carbonyl reductase 1; Prostaglandin 9 ketoreductase; SDR21C1.
Gene ID
873
Swiss Prot
P16152
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Human
Target
CBR1
Clonality
Recombinant
Conjugation
FITC
Source
KLH conjugated synthetic peptide derived from human CBR1
Applications
WB, IF
Purification
Purified by Protein A.
Excitation Emission
494nm/518nm
Concentration
Lot dependent
Dilution
WB (1:300-5000), IF ()
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
873
Isotype
IgG
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
C2442-03-HRP 100 µL
CD94 (KLRD1, Killer cell lectin-like receptor, subfamily D, member 1, Kp43) (HRP) discontinued
Ask
View Details 
B2019172 100 µg
GALP (3-32) (Human), Agonist of GAL 1 Receptor; Agonist of GAL 2 Receptor
Ask
View Details 